posts browsing tag

macrogen

– The largest number of regions and races included in any Asian reference panel – Identification of genome diversity within Asian ethnic groups and differences in drug response SEOUL, South Korea–The precision medicine and biotechnology company Macrogen (Chairman Jung-Sun Seo) (KOSDAQ: 038290) announced on Dec 4 that …

Continue reading

– Patent granted for blockchain technology for data transaction brokerage and sharing between data providers and users – Allows individuals to have control over their healthcare data – Technology to be used by Psomagen to build healthcare big data for the U.S. DTC market SEOUL, South Korea— The precision …

Continue reading

–  Share subscription agreement of 4.1million AUD with Microba –  Microbiome database construction in Asia Pacific region within the year, followed by global service launch in early 2020 –  Plans to preempt global microbiome market with close business cooperation SEOUL, South Korea–Precision medicine and biotechnology company, Macrogen …

Continue reading

– Macrogen is the first and only NGS-based institute in Korea to receive GCLP accreditation – Increased demands from multinational pharmaceutical companies for NGS analysis for companion diagnostics and targeted anti-cancer drugs – Expected growth in revenue by entering into the clinical trial market with a new profit …

Continue reading

SEOUL, South Korea–The precision medicine and biotechnology company, Macrogen (CEO Kap-Seok Yang, www.macrogen.com) (KOSDAQ: 038290), announced on December 20 that its NGS clinical laboratories in Seoul headquarters and Bundang Precision Medicine Center had officially received CLIA (Clinical Laboratory Improvement Amendments) accreditation, as the first in …

Continue reading